Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  ERYTECH Pharma    ERYP   FR0011471135

ERYTECH PHARMA

(ERYP)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
03/14/2019 03/15/2019 03/18/2019 03/19/2019 03/20/2019 Date
8.2(c) 8(c) 7.66(c) 7.65(c) 7.67 Last
38 009 40 010 61 636 15 383 7 786 Volume
0.00% -2.44% -4.25% -0.13% +0.26% Change
More quotes
Financials (EUR)
Sales 2019 8,23 M
EBIT 2019 -52,9 M
Net income 2019 -54,6 M
Finance 2019 73,8 M
Yield 2019 -
Sales 2020 15,9 M
EBIT 2020 -47,9 M
Net income 2020 -48,3 M
Finance 2020 23,1 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 7,70x
EV / Sales2020 7,20x
Capitalization 137 M
More Financials
Company
ERYTECH Pharma is a French biopharmaceutical company providing new prospects for cancer patients. By encapsulating the asparaginase enzyme in red blood cells, has developed eryaspase/GRASPA®, an innovative treatment that destroys cancerous cells through starvation while significantly reducing side... 
More about the company
Surperformance© ratings of ERYTECH Pharma
Trading Rating : Investor Rating :
More Ratings
Latest news on ERYTECH PHARMA
03/11ERYTECH PHARMA : Provides Business Update and Reports Financial Results for Full..
GL
03/11ERYTECH PHARMA : to Present at Cowen and Company 39th Annual Healthcare Conferen..
AQ
03/11ERYTECH PHARMA : Presents Findings at European Red Cell Research Society Meeting
AQ
03/08ERYTECH PHARMA : to Present at Cowen & Company 39th Annual Healthcare Conference..
AQ
03/07ERYTECH PHARMA : to Host Fourth Quarter and Full Year 2018 and Business Update
AQ
03/06ERYTECH PHARMA SA : annual earnings release
03/06ERYTECH PHARMA : to Host Fourth Quarter and Full Year 2018 Conference Call and B..
AQ
01/21ERYTECH PHARMA : Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019 ASCO GI..
AQ
01/18ERYTECH PHARMA : Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019 ASCO GI..
AQ
2018ERYTECH PHARMA : Partners with New York Blood Center for Red Blood Cell Supply a..
GL
More news
Analyst Recommendations on ERYTECH PHARMA
More recommendations
Sector news : Bio Therapeutic Drugs
03/11Regeneron Says FDA Approves Dupixent for Atopic Dermatitis in Adolescents
DJ
03/08Regeneron, Sanofi Get FDA Priority Review for Dupixent
DJ
03/07SHANGHAI RAAS BLOOD PRODUCTS : Spain's Grifols, China's Shanghai RAAS form strat..
RE
03/06GILEAD SCIENCES : Says Once-Daily HIV Regimen Shows Promise in Treating Teens an..
DJ
03/05FDA Approves Controversial Drug for Depression -- Update
DJ
More sector news : Bio Therapeutic Drugs
Chart ERYTECH PHARMA
Duration : Period :
ERYTECH Pharma Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ERYTECH PHARMA
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 28,1 €
Spread / Average Target 267%
EPS Revisions
Managers
NameTitle
Gil Beyen Chairman, CEO & Head-Investor Relations
Eric Soyer Chief Operating & Financial Officer
Iman El-Hariry Chief Medical Officer
Alexander Scheer Chief Scientific Officer
Philippe Archinard Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ERYTECH PHARMA22.40%156
GILEAD SCIENCES4.70%83 533
VERTEX PHARMACEUTICALS13.15%46 468
REGENERON PHARMACEUTICALS8.97%43 697
GENMAB4.54%10 456
SAREPTA THERAPEUTICS INC15.89%9 318